ERBB2 and gastric cancer: Despite remarkable advances in targeted therapy for molecular targets, vascular endothelial growth factor receptor (VEGFR), and human epidermal growth factor receptor 2 (HER2) to improve patient survival in the setting of recurrent and metastatic GC, the prognosis of patients with recurrent and metastatic GC remains poor [3].